EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model

Shivani S Godbole iD, Dongxiao Sun iD, Matthew D Coates, Victoria J Himmelberger, Diana E Roopchand iD, Wesley M Raup-Konsavage iD

Journal of Clinical Medicine · 28.08.2025 · 14 (17) · 6095

DOI: 10.3390/jcm14176095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.08.2025. Verfasst von Shivani S Godbole und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCCIH NIH HHS, PA Options for Wellness, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ulcerative colitis (UC) is an autoimmune disorder characterized by inflammation of the mucosa that gives rise to a disrupted epithelial morphology. Persistent or recurrent inflammation and the debilitating nature of the associated symptoms make treatment of UC challenging. Cannabinoids derived from Cannabis sativa L. have been used for treatment of gastrointestinal disorders due to the wide-ranging therapeutic benefits of these compounds.

Methods

We evaluated a commercial hemp extract, high in cannabigerol (CBG) and cannabidiol (CBD), as a novel treatment for UC symptoms using the dextran sodium sulfate (DSS) model in mice. Hemp extract was administered via two different routes of administration, intraperitoneal (i.p) and oral (p.o).

Results

Specifically, we observed that cannabinoid treatment reduced damage to the colonic epithelium. We also observed that CBG/CBD rich hemp extracts help reduce pain-related responses in these animals.

Conclusions

Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management.

Schlagwörter

Stichwörter der Autor:innen

Cannabis sativaDSS model in micecannabidiolcannabigerolulcerative colitis

Autor:innen und Institutionen

  • Department of Neuroscience & Experimental Therapeutics, Penn State College of Medicine, Hershey, PA 17033, USA.
  • Center for Cannabis & Natural Product Pharmaceutics, Penn State College of Medicine, Hershey, PA 17033, USA.
  • Department of Medicine, Penn State College of Medicine, Hershey, PA 17033, USA.
  • Department of Food Science, Rutgers University, New Brunswick, NJ 08901, USA.

ORCID-Profile: Shivani S Godbole, Dongxiao Sun, Diana E Roopchand, Wesley M Raup-Konsavage

Förderung

  • NCCIH NIH HHS
  • PA Options for Wellness
  • NIH HHS
  • NIH/NCCIH

Zitieren

APA

Godbole, S. S., Sun, D., Coates, M. D., Himmelberger, V. J., Roopchand, D. E., & Raup-Konsavage, W. M. (2025). Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. Journal of Clinical Medicine, 14(17), 6095. https://doi.org/10.3390/jcm14176095

Vancouver

Godbole SS, Sun D, Coates MD, Himmelberger VJ, Roopchand DE, Raup-Konsavage WM. Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. Journal of Clinical Medicine. 2025;14(17):6095. doi:10.3390/jcm14176095

BibTeX
@article{Godbole2025,
  author = {Godbole, Shivani S and Sun, Dongxiao and Coates, Matthew D and Himmelberger, Victoria J and Roopchand, Diana E and Raup-Konsavage, Wesley M},
  title = {Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {17},
  pages = {6095},
  doi = {10.3390/jcm14176095}
}
Kostenlos starten →